ArticleAME case reports2026
Primary malignant melanoma of the esophagus: a case report.
Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary malignant melanoma of the esophagus (PMME) is an extremely rare malignant tumor with a poor prognosis. PMME accounts for 0.1% to 0.2% of all malignant esophageal tumors. Owing to its rarity and heterogeneity, there is currently a lack of standardized diagnostic and therapeutic guidelines, making clinical management challenging. Herein, we report this case to describe its clinicopathological features, treatment strategy, and clinical course. Case Description: A 65-year-old Asian male patient presented with a two-month history of dysphagia. Upper gastrointestinal endoscopy revealed a large intraluminal mass in the middle to lower thoracic esophagus, and endoscopic biopsy suggested esophageal malignant melanoma. Postoperative histopathological and immunohistochemical examination confirmed malignant melanoma. Targeted physical evaluation of alternative potential primary sites and positron emission tomography/computed tomography (PET/CT) imaging revealed no additional primary lesions, supporting a primary esophageal origin. The patient underwent radical surgical resection followed by adjuvant chemotherapy, including nab-paclitaxel and carboplatin. At the final telephone follow-up approximately 28 months after surgery, no recurrence or distant metastasis was reported, and the patient maintained a good overall health status. Conclusions: This case describes a favorable clinical course following microscopically margin-negative resection and individualized adjuvant chemotherapy in a patient with localized PMME. However, the contribution of adjuvant chemotherapy to the outcome remains uncertain, and further studies are needed to establish optimal postoperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.